

Robert M Samstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/890142/publications.pdf>

Version: 2024-02-01

44
papers

12,746
citations

147786
31
h-index

254170
43
g-index

47
all docs

47
docs citations

47
times ranked

25301
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	17.5	110
2	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. <i>Nature Genetics</i> , 2022, 54, 996-1012.	21.4	30
3	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	6.3	38
4	Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100615.	1.2	6
5	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	21.4	139
6	Taking CAR T cells up a synthetic Notch. <i>Nature Reviews Immunology</i> , 2021, 21, 135-135.	22.7	3
7	Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives. <i>Lung Cancer</i> , 2021, 152, 157-164.	2.0	6
8	Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 757804.	4.8	31
9	Supporting the next generation of scientists to lead cancer immunology research. <i>Cancer Immunology Research</i> , 2021, 9, canimm.0519.2021.	3.4	1
10	Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin. <i>Nature Biomedical Engineering</i> , 2021, 5, 983-997.	22.5	30
11	Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. <i>Cancer Cell</i> , 2021, 39, 1594-1609.e12.	16.8	151
12	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 112-115.	3.3	47
13	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	13.2	114
14	Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. <i>Cell</i> , 2020, 183, 1634-1649.e17.	28.9	103
15	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	14.3	1,387
16	DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden. <i>Cell Reports Medicine</i> , 2020, 1, 100034.	6.5	46
17	Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 1135-1140.	7.0	33
18	Advancing scientific knowledge in times of pandemics. <i>Nature Reviews Immunology</i> , 2020, 20, 338-338.	22.7	49

#	ARTICLE	IF	CITATIONS
19	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019, 25, 767-775.	30.7	282
20	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	12.6	395
21	An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 697-708.	0.8	62
22	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
23	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 3435-3447.	8.2	33
24	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	12.6	834
25	The DNA damage response in immunotherapy and radiation. <i>Advances in Radiation Oncology</i> , 2018, 3, 527-533.	1.2	24
26	Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. <i>Advances in Radiation Oncology</i> , 2018, 3, 391-398.	1.2	33
27	Dissecting microsatellite instability in colorectal cancer: one size does not fit all. <i>Genome Medicine</i> , 2017, 9, 45.	8.2	4
28	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. <i>Head and Neck</i> , 2016, 38, 1310-1317.	2.0	65
29	Unilateral Suppression of Brown Fat on FDG PET/CT in Horner Syndrome. <i>Clinical Nuclear Medicine</i> , 2016, 41, 797-798.	1.3	5
30	Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy. <i>Journal of Skin Cancer</i> , 2014, 2014, 1-7.	1.2	37
31	Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells. <i>Nature Immunology</i> , 2014, 15, 580-587.	14.5	193
32	A comparative encyclopedia of DNA elements in the mouse genome. <i>Nature</i> , 2014, 515, 355-364.	27.8	1,444
33	Mouse regulatory DNA landscapes reveal global principles of cis-regulatory evolution. <i>Science</i> , 2014, 346, 1007-1012.	12.6	244
34	Foxp3 Exploits a Pre-Existent Enhancer Landscape for Regulatory T Cell Lineage Specification. <i>Cell</i> , 2012, 151, 153-166.	28.9	411
35	Extrathymic Generation of Regulatory T Cells in Placental Mammals Mitigates Maternal-Fetal Conflict. <i>Cell</i> , 2012, 150, 29-38.	28.9	534
36	Transcription factor Foxp3 and its protein partners form a complex regulatory network. <i>Nature Immunology</i> , 2012, 13, 1010-1019.	14.5	377

#	ARTICLE	IF	CITATIONS
37	Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation. <i>Immunity</i> , 2011, 34, 566-578.	14.3	799
38	Luteinizing Hormone-Releasing Hormone Enhances T Cell Recovery following Allogeneic Bone Marrow Transplantation. <i>Journal of Immunology</i> , 2009, 182, 5846-5854.	0.8	75
39	CD4 ⁺ Regulatory T Cells Control T _H 17 Responses in a Stat3-Dependent Manner. <i>Science</i> , 2009, 326, 986-991.	12.6	895
40	The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. <i>Biomaterials</i> , 2008, 29, 703-708.	11.4	76
41	Regulatory T Cell Reconstitution is Delayed Following Allogeneic Bone Marrow Transplantation. <i>FASEB Journal</i> , 2008, 22, 862.20.	0.5	0
42	Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. <i>Nature Medicine</i> , 2006, 12, 657-664.	30.7	697
43	Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. <i>Biomaterials</i> , 2005, 26, 5727-5736.	11.4	174
44	Osteoclasts Are Involved in Stem Cell Mobilization: Cleavage of SDF-1 by Cathepsin K.. <i>Blood</i> , 2004, 104, 1291-1291.	1.4	14